Beranda › Penyakit Autoimun › North Carolina › Durham
Uji klinis Penyakit Autoimun di Durham, NC
15 studi untuk Penyakit Autoimun mencari peserta di lokasi sekitar Durham (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Environmental Risk Factors for the Anti-synthetase Syndrome
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- NIEHS Clinical Research Unit (CRU), Research Triangle Park · 7 mi jauhnya
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Menerima pesertaFase 3
- Duke University Hospital, Durham
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Menerima pesertaFase 2/3
- Duke University Medical Center - Accepting Young Adults and Juvenile Patients, Durham
- University of North Carolina at Chapel Hill - Accepting Adult Patients, Chapel Hill · 10 mi jauhnya
Daratumumab in Primary Antiphospholipid Syndrome
Menerima pesertaFase 1/2
- Duke University, Durham
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Menerima pesertaFase 1
- Duke University Medical Center, Durham
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Menerima pesertaFase 3
- Duke University Hospital, Durham
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
Menerima pesertaFase 3
- GSK Investigational Site, Durham
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Menerima pesertaFase 1/2
- UNC Chapel Hill, Chapel Hill · 10 mi jauhnya
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Menerima pesertaFase 2/3
- Duke University, Durham
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Menerima pesertaFase 3
- Duke University Medical Center, Durham
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Menerima pesertaFase 3
- Site Number - 1013, Durham
- Site Number - 1020, Chapel Hill · 10 mi jauhnya
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Menerima pesertaFase 1
- Duke University, Durham
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Menerima pesertaStudi observasional
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi jauhnya
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Menerima pesertaFase 1
- Duke University Health System, Durham
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Duke University, Durham
Uji klinis Penyakit Autoimun di kota lain
- Houston, TX21 studi
- Washington, DC19 studi
- New York City, NY19 studi
- Philadelphia, PA16 studi
- Boston, MA13 studi
- Los Angeles, CA12 studi
- Chicago, IL12 studi
- Dallas, TX9 studi
- Cleveland, OH8 studi
- Atlanta, GA8 studi
- Milwaukee, WI8 studi
- Portland, OR8 studi
Studi lain di Durham
- Kanker Payudara63 studi
- Kanker (semua jenis)58 studi
- Kanker Paru Non-Sel Kecil39 studi
- Mieloma Multipel37 studi
- Kanker Metastatik33 studi
- Leukemia Mieloid Akut33 studi
- Kanker Paru32 studi
- Kanker Prostat32 studi
- Kanker Kolorektal28 studi
- Leukemia Limfositik Kronis27 studi
- Kanker Ovarium27 studi
- Gagal Jantung26 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.